Peter Bach
Changing the drug pricing game
TEDMED Talks are available, free to the world, thanks to our partners.
About Peter Bach
Peter Bach is a physician, epidemiologist, researcher and healthcare policy expert on the cost and value of drugs in the United States. Through the Drug Pricing Lab, Peter and his team share information and research on drug development and pricing, and, based on evidence and research, promote policy reforms aimed to reduce the cost of drugs while ensuring innovation for the future. In 2015, Peter released DrugAbacus, the first ever interactive tool to help determine the price of a cancer drug based on its value compared with the price assigned by the pharmaceutical company. Peter has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He is a member of the National Academy of Medicine and the American Society of Clinical Investigation. Peter has been a faculty member of Memorial Sloan Kettering’s Department of Epidemiology and Biostatistics since 1998.
Find out moreAbout This Talk
Americans pay more for prescription drugs than people in most other Western countries. And unfortunately, high drug costs mean low accessibility for many of those in need of life-saving medications. Peter Bach envisions a different approach to pharmaceutical pricing. As Director of Memorial Sloan Kettering Hospital’s Center for Health Policy and Outcomes and the founder of the Drug Pricing Lab, Peter and his team strive to identify more rational approaches to drug pricing and to bring transparency to the process.
Tune in to Peter’s 2017 TEDMED Talk to learn how he is working to balance getting patients the critical treatments they need, while also ensuring drug developers have adequate funding to research, improve, and develop important therapeutics.
Tune in to Peter’s 2017 TEDMED Talk to learn how he is working to balance getting patients the critical treatments they need, while also ensuring drug developers have adequate funding to research, improve, and develop important therapeutics.